2106 | Parkinson disease |
1952 | Humans |
1358 | Human |
1214 | Male |
1073 | Female |
944 | Middle Aged |
914 | Aged |
770 | Nervous system diseases |
628 | Treatment |
621 | Parkinson Disease (physiopathology) |
546 | Animals |
485 | Adult |
472 | Parkinson Disease (drug therapy) |
382 | Parkinson Disease (therapy) |
324 | Parkinson Disease (complications) |
291 | Chemotherapy |
261 | Antiparkinson agent |
259 | Parkinson Disease (pathology) |
248 | Parkinson's disease |
248 | Animal |
244 | Parkinson Disease (metabolism) |
234 | Review |
231 | Subthalamic nucleus |
230 | Aged, 80 and over |
228 | Dopamine |
227 | Levodopa |
225 | Antiparkinson Agents (therapeutic use) |
208 | Parkinson Disease (genetics) |
205 | Levodopa (therapeutic use) |
195 | Parkinson Disease (psychology) |
184 | Disease Models, Animal |
180 | Treatment Outcome |
168 | Rats |
166 | Rat |
165 | Elderly |
161 | Toxicity |
160 | Degenerative disease |
153 | Parkinson Disease (diagnosis) |
150 | France |
148 | Pathophysiology |
142 | Exploration |
142 | Dopamine (metabolism) |
137 | Neuropsychological Tests |
137 | Alzheimer disease |
132 | Antiparkinson Agents (adverse effects) |
129 | Dopaminergic neuron |
127 | Comparative study |
125 | Parkinsonism |
123 | Severity of Illness Index |
123 | Levodopa (adverse effects) |
117 | Basal ganglion |
117 | Animal model |
115 | Subthalamic Nucleus (physiology) |
115 | Diagnosis |
111 | Mice |
108 | Corpus striatum |
107 | Deep Brain Stimulation (methods) |
106 | Pathogenesis |
106 | Parkinson Disease (epidemiology) |
106 | Locus niger |
106 | Dyskinesia |
105 | Mutation |
101 | Case-Control Studies |
101 | Case study |
99 | Brain (vertebrata) |
97 | Complication |
96 | Time Factors |
96 | Deep brain stimulation |
93 | Follow-Up Studies |
92 | Dopamine agonist |
90 | Wolff Parkinson White syndrome |
89 | Surgery |
89 | Subthalamic Nucleus (physiopathology) |
89 | Parkinson Disease (surgery) |
86 | Neurons (metabolism) |
85 | Adolescent |
84 | Mouse |
84 | Cardiovascular disease |
83 | Dementia |
82 | Electrodes, Implanted |
82 | Deep Brain Stimulation |
81 | Depression |
80 | Instrumental stimulation |
78 | Parkinson Disease, Secondary (chemically induced) |
78 | Magnetic Resonance Imaging |
78 | Degeneration |
78 | Agonist |
76 | Cognitive disorder |
75 | Child |
74 | Risk Factors |
74 | Epidemiology |
73 | Prospective Studies |
73 | Prognosis |
73 | Cognition |
72 | Substantia Nigra (pathology) |
72 | Neuron |
72 | Immunohistochemistry |
72 | Electrical stimulus |
71 | Electrophysiology |
71 | Electric Stimulation Therapy |
71 | Brain (pathology) |
70 | Antiparkinson Agents (administration & dosage) |
68 | Neurons (pathology) |
68 | Monkey |
68 | Medicine |
68 | Encephalon |
68 | Double-Blind Method |
67 | Parkinson Disease (etiology) |
67 | Parkinson Disease (diagnostic imaging) |
67 | Neurons (physiology) |
67 | Mechanism of action |
67 | Corpus Striatum (metabolism) |
67 | Cell death |
65 | Risk factor |
65 | Pallidum |
65 | Multiple system atrophy |
65 | Dopamine (physiology) |
65 | Brain (metabolism) |
65 | Arrhythmia |
64 | Prevalence |
64 | Genetics |
63 | Retrospective Studies |
63 | Oxidopamine |
63 | Neurotoxin |
63 | Emission tomography |
62 | Substantia Nigra (metabolism) |
62 | Analysis of Variance |
61 | Rats, Sprague-Dawley |
61 | Levodopa (pharmacology) |
61 | Dose-Response Relationship, Drug |
60 | Levodopa (administration & dosage) |
60 | Instrumentation therapy |
60 | Disease Progression |
60 | Brain (physiopathology) |
60 | Apoptosis |
59 | Central nervous system |
58 | Tremor |
58 | Symptomatology |
58 | Evolution |
58 | Antiparkinson Agents (pharmacology) |
55 | Dopamine Agonists (therapeutic use) |
54 | Neuroprotective agent |
54 | Electrocardiography |
53 | Reference Values |
53 | Rats, Wistar |
53 | In vitro |
53 | D2 Dopamine receptor |
52 | Tyrosine 3-Monooxygenase (metabolism) |
52 | Nuclear magnetic resonance imaging |
52 | Chronic |
51 | Movement (physiology) |
51 | Electromyography |
51 | Diagnosis, Differential |
50 | Subthalamic Nucleus (surgery) |
50 | Posture |
50 | Dopamine receptor |
49 | Neurons (drug effects) |
49 | Mice, Inbred C57BL |
49 | Deep Brain Stimulation (adverse effects) |
49 | Brain Mapping |
48 | Thalamus |
48 | Oxidative stress |
47 | Surveys and Questionnaires |
47 | Psychotropic |
47 | Parkinson Disease, Secondary (physiopathology) |
47 | Differential diagnostic |
46 | Young Adult |
46 | Public health |
46 | Indication |
46 | Genotype |
45 | deep brain stimulation |
45 | Technique |
45 | Huntington disease |
45 | High frequency |
45 | Gene |
45 | Dyskinesia, Drug-Induced (etiology) |
45 | Cognition Disorders (etiology) |
45 | Basal Ganglia (physiopathology) |
44 | Treatment efficiency |
44 | France (epidemiology) |
44 | Etiology |
44 | Dopa |
43 | Stimulation |
43 | Stereotaxic Techniques |
43 | Reproducibility of Results |
43 | Psychometrics |
43 | Phenotype |
43 | Gene expression |
43 | Cross-Sectional Studies |
42 | Incidence |
42 | Age of Onset |
41 | Pain |
41 | Electrodiagnosis |
40 | Supranuclear ophthalmoplegia |
40 | Midbrain |
40 | Long term |
40 | Electroencephalography |
40 | Dystonia |
40 | Drug Therapy, Combination |
40 | Age Factors |
39 | dopamine |
39 | basal ganglia |
39 | Reaction Time (physiology) |
39 | Quality of Life |
39 | Lesion |
39 | Evaluation |
39 | Europe |
38 | subthalamic nucleus |
38 | Sleep disorder |
38 | Recommendation |
38 | Psychomotor Performance (physiology) |
38 | Nigrostriatal pathway |
38 | Neurologic Examination |
38 | Motor Activity (drug effects) |
38 | Macaca fascicularis |
38 | Corpus Striatum (pathology) |
37 | Substantia Nigra (physiopathology) |
37 | Statistics, Nonparametric |
37 | Experimental disease |
37 | Drug |
37 | Corpus Striatum (drug effects) |
36 | Senescence |
36 | Motor control |
36 | Gerontology |
36 | Dyskinesia, Drug-Induced (physiopathology) |
36 | Behavior |
35 | alpha-Synuclein (metabolism) |
35 | Positron emission tomography |
35 | Motor system disorder |
35 | Globus Pallidus (physiopathology) |
35 | Genetic Predisposition to Disease |
35 | Bilateral |
34 | Prevention |
34 | Neuroleptic |
34 | Corpus Striatum (physiopathology) |
33 | Wolff-Parkinson-White Syndrome (physiopathology) |
33 | Tomography, Emission-Computed, Single-Photon |
33 | Psychiatric Status Rating Scales |
33 | Mutation (genetics) |
33 | Evaluation scale |
33 | Clinical Trials as Topic |
32 | Photon |
32 | Parkinson’s disease |
32 | Motor Activity (physiology) |
32 | Magnetic Resonance Imaging (methods) |
32 | Heart |
32 | Cohort Studies |
32 | Cerebral disorder |
32 | Age |
31 | Reeducation |
31 | Oral administration |
31 | Neuroprotective Agents (therapeutic use) |
31 | Glutamate |
31 | Gene therapy |
31 | Gait Disorders, Neurologic (etiology) |
31 | Electric Stimulation |
31 | Brain (drug effects) |
30 | Parkinson Disease, Secondary (pathology) |
30 | Nerve Degeneration (pathology) |
30 | Lewy body |
30 | Functional Laterality |
30 | Functional Laterality (physiology) |
30 | Epilepsy |
30 | Electric Stimulation Therapy (methods) |
30 | Dopaminergic pathway |
30 | Dopamine Agonists (adverse effects) |
30 | Apathy |
30 | Antagonist |
30 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
29 | Wolff-Parkinson-White Syndrome (surgery) |
29 | Positron-Emission Tomography |
29 | Motor Cortex (physiopathology) |
29 | Metabolism |
29 | Mental disorder |
29 | Disability Evaluation |
29 | Clinical management |
29 | Body movement |
29 | Advanced stage |
28 | Ubiquitin-Protein Ligases (genetics) |
28 | Ropinirole |
28 | Psychosis |
28 | Neurology |
28 | Mitochondria |
28 | Mice, Knockout |
28 | Malignant tumor |
28 | Iron |
28 | Extrapyramidal syndrome |
27 | Tyrosine 3-monooxygenase |
27 | Quality of life |
27 | Pathology |
27 | Mesencephalon (pathology) |
27 | Enzyme inhibitor |
27 | Emotion emotionality |
27 | Dyskinesia, Drug-Induced (drug therapy) |
27 | Dopamine Agonists (pharmacology) |
27 | Dopamine Agents (therapeutic use) |
27 | Disease |
27 | Combined Modality Therapy |
27 | Cognition Disorders (diagnosis) |
27 | Bromocriptine |
27 | Association |
27 | Activities of Daily Living |
26 | Subthalamic Nucleus (pathology) |
26 | Substantia Nigra (drug effects) |
26 | Protein-Serine-Threonine Kinases (genetics) |
26 | Predictive Value of Tests |
26 | Pharmacokinetics |
26 | Parkinson Disease (enzymology) |
26 | Neural Pathways (physiopathology) |
26 | Nerve Tissue Proteins (genetics) |
26 | Models |
26 | Models, Neurological |
26 | Lewy body dementia |
26 | Dopaminergic Neurons (metabolism) |
26 | Behavioral disorder |
26 | Basal Ganglia (pathology) |
25 | alpha-Synuclein (genetics) |
25 | Wolff-Parkinson-White Syndrome (diagnosis) |
25 | Tomography, Emission-Computed |
25 | Reaction Time |
25 | Positron |
25 | Mesencephalon (metabolism) |
25 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
25 | Gait disorder |
25 | Dysarthria |
25 | Cognition (physiology) |
25 | Clinical trial |
25 | Brain |
25 | Basal Ganglia (metabolism) |
25 | Amyotrophic lateral sclerosis |
24 | Neuroprotective Agents (pharmacology) |
24 | Motor cortex |
24 | Genetic determinism |
24 | Gait (physiology) |
24 | Electrodes |
24 | Electric Stimulation Therapy (adverse effects) |
24 | Dopamine Agonists (administration & dosage) |
24 | Cells, Cultured |
24 | Catecholamine |
24 | Behavior, Animal (drug effects) |
23 | substantia nigra |
23 | levodopa |
23 | Walking |
23 | Speech |
23 | Serotonin |
23 | Sensitivity and Specificity |
23 | Pesticides |
23 | Pedigree |
23 | Parkinson Disease, Secondary (drug therapy) |
23 | Parkinson Disease (blood) |
23 | Movement Disorders (physiopathology) |
23 | Models, Biological |
23 | Memory |
23 | Memory disorder |
23 | Idiopathic |
23 | Hallucination |
23 | Graft |
23 | Frontal Lobe (physiopathology) |
23 | Free radical |
23 | Executive function |
23 | Double blind study |
23 | Depression (etiology) |
23 | Denervation |
23 | Brain (diagnostic imaging) |
22 | Tremor (therapy) |
22 | Polysomnography |
22 | Motricity |
22 | MPTP |
22 | Inflammation |
22 | In vivo |
22 | Geriatrics |
22 | Gait |
22 | Family study |
22 | Experimental study |
22 | Early |
22 | Consensus conference |
22 | Comorbidity |
22 | Child, Preschool |
22 | Cerebral Cortex (physiopathology) |
22 | Biological activity |
22 | Akinesia |
21 | rat |
21 | dementia |
21 | Multiple sclerosis |
21 | Motivation |
21 | Locomotion |
21 | Image Processing, Computer-Assisted |
21 | Gait Disorders, Neurologic (physiopathology) |
21 | Drug combination |
21 | Dementia (diagnosis) |
21 | Cognition Disorders (physiopathology) |
21 | Cerebral cortex |
21 | Biological receptor |
21 | Alzheimer Disease (physiopathology) |
21 | Alzheimer Disease (metabolism) |
20 | Tyrosine 3-Monooxygenase (analysis) |
20 | Transplantation |
20 | Thalamic Nuclei (physiopathology) |
20 | Schizophrenia |
20 | Safety |
20 | Rapid eye movement sleep |
20 | RNA, Messenger (metabolism) |
20 | Progressive |
20 | Pilot Projects |
20 | Performance evaluation |
20 | Parkinsonian Disorders (metabolism) |
20 | Parkinson Disease (history) |
20 | Movement |
20 | Limbic system |
20 | Kinetics |
20 | Involuntary movement |
20 | In Situ Hybridization |
20 | Health |
20 | Ergot derivatives |
20 | Drug Administration Schedule |
20 | Dopaminergic Neurons (drug effects) |
20 | Bromocriptine (therapeutic use) |
20 | Antidepressant agent |
20 | Alzheimer Disease (pathology) |
19 | Tremor (physiopathology) |
19 | Subthalamic Nucleus |
19 | Stem cell |
19 | Pramipexole |
19 | Placebo |
19 | Parkinsonian Disorders (pathology) |
19 | Parkinson |
19 | Neurons (cytology) |
19 | NMDA receptor |
19 | Movement Disorders (therapy) |
19 | Movement Disorders (etiology) |
19 | Mitochondria (metabolism) |
19 | Lewy Bodies (pathology) |
19 | History, 20th Century |
19 | History, 19th Century |
19 | Excitability disorder |
19 | Deep Brain Stimulation (instrumentation) |
19 | Clinical investigation |
19 | Autoradiography |
19 | Apomorphine (pharmacology) |
19 | Apomorphine (administration & dosage) |
19 | Antioxidant |
18 | Postural hypotension |
18 | Phosphorylation |
18 | Neuroprotection |
18 | Nerve Net (physiopathology) |
18 | Mice, Transgenic |
18 | Macaca mulatta |
18 | Longitudinal Studies |
18 | Lipids |
18 | Learning |
18 | Facial Expression |
18 | Dysfunction |
18 | Dopaminergic transmission |
18 | DNA Mutational Analysis |
18 | Cell Death (physiology) |
18 | Bromocryptine |
18 | Behavior, Animal |
18 | Apomorphine (therapeutic use) |
18 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
17 | Synucleins |
17 | Subthalamic Nucleus (metabolism) |
17 | Stereotaxic surgery |
17 | Signal Transduction |
17 | Sex Factors |
17 | Risk |
17 | Psychomotor Performance (drug effects) |
17 | Postural Balance (physiology) |
17 | Polymorphism |
17 | Piribedil |
17 | Parkinsonian Disorders (physiopathology) |
17 | Oxidopamine (toxicity) |
17 | Norepinephrine |
17 | Methodology |
17 | Globus Pallidus (surgery) |
17 | Genetic Predisposition to Disease (genetics) |
17 | Fall |
17 | Environment |
17 | Cross-Over Studies |
17 | Concomitant disease |
17 | Cognition Disorders (psychology) |
17 | Classification |
17 | Cell Count |
17 | Catheter Ablation |
17 | Biomechanical Phenomena |
17 | Bibliographic review |
17 | Attention |
17 | Attention (physiology) |
17 | Ageing |
16 | alpha-Synuclein |
16 | Thalamus (surgery) |
16 | Single photon emission tomography |
16 | Primates |
16 | Photic Stimulation |
16 | Pharmacotherapy |
16 | Parkinson Disease, Secondary (metabolism) |
16 | Neurotransmitter |
16 | Neurosurgical Procedures |
16 | Neurons (enzymology) |
16 | Neurodegenerative Diseases (physiopathology) |
16 | Multivariate Analysis |